465 related articles for article (PubMed ID: 22897731)
21. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous stem-cell transplantation on outcome.
Martín A; Caballero MD;
Haematologica; 2009 May; 94(5):744. PubMed ID: 19336744
[No Abstract] [Full Text] [Related]
22. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype.
Song KW; Mollee P; Keating A; Crump M
Br J Haematol; 2003 Mar; 120(6):978-85. PubMed ID: 12648067
[TBL] [Abstract][Full Text] [Related]
23. A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.
Lim ST; Fayad L; Tulpule A; Modiano M; Cabanillas F; Laffranchi B; Allievi C; Bernareggi A; Levine AM
Leuk Lymphoma; 2007 Feb; 48(2):374-80. PubMed ID: 17325899
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: a prospective randomized trial in Algeria.
Aribi M; Mesli N; Remla N; Sari BE; Taleb A; Touhami H; Bekadja MA; Zouaoui-Benhadji Z; Bouzid K; Meguenni K
J Cancer Res Ther; 2010; 6(1):41-6. PubMed ID: 20479546
[TBL] [Abstract][Full Text] [Related]
25. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.
Popat U; Przepiork D; Champlin R; Pugh W; Amin K; Mehra R; Rodriguez J; Giralt S; Romaguera J; Rodriguez A; Preti A; Andersson B; Khouri I; Claxton D; de Lima M; Donato M; Anderlini P; Gajewski J; Cabanillas F; van Besien K
J Clin Oncol; 1998 Jan; 16(1):63-9. PubMed ID: 9440724
[TBL] [Abstract][Full Text] [Related]
26. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.
Labrador J; Cabrero-Calvo M; Pérez-López E; Mateos MV; Vázquez L; Caballero MD; García-Sanz R
Ann Hematol; 2014 Oct; 93(10):1745-53. PubMed ID: 24863692
[TBL] [Abstract][Full Text] [Related]
27. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
[TBL] [Abstract][Full Text] [Related]
28. Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors.
Telio D; Fernandes K; Ma C; Tsang R; Keating A; Crump M; Kuruvilla J
Leuk Lymphoma; 2012 May; 53(5):836-41. PubMed ID: 22136378
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
Boonlerd P; Tantiworawit A; Norasetthada L; Chai-Adisaksopha C; Punnachet T; Hantrakun N; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Rattarittamrong E
Ann Med; 2023; 55(2):2261109. PubMed ID: 37748107
[TBL] [Abstract][Full Text] [Related]
30. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Ayers EC; Li S; Medeiros LJ; Bond DA; Maddocks KJ; Torka P; Mier Hicks A; Curry M; Wagner-Johnston ND; Karmali R; Behdad A; Fakhri B; Kahl BS; Churnetski MC; Cohen JB; Reddy NM; Modi D; Ramchandren R; Howlett C; Leslie LA; Cytryn S; Diefenbach CS; Faramand R; Chavez JC; Olszewski AJ; Liu Y; Barta SK; Mukhija D; Hill BT; Ma H; Amengual JE; Nathan S; Assouline SE; Orellana-Noia VM; Portell CA; Chandar A; David KA; Giri A; Hess BT; Landsburg DJ
Cancer; 2020 Jan; 126(2):293-303. PubMed ID: 31568564
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of high-dose cyclophosphamide, etoposide and ranimustine regimen followed by autologous peripheral blood stem cell transplant for patients with diffuse large B-cell lymphoma.
Kobayashi Y; Hatta Y; Sugitani M; Hojo A; Nakagawa M; Kusuda M; Uchino Y; Takahashi H; Kiso S; Hirabayashi Y; Yagi M; Kodaira H; Kurita D; Miura K; Iriyama N; Kobayashi S; Kura Y; Horikoshi A; Sawada U; Takeuchi J; Takei M
Leuk Lymphoma; 2014 Nov; 55(11):2514-9. PubMed ID: 24491027
[TBL] [Abstract][Full Text] [Related]
32. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
33. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G
Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680
[TBL] [Abstract][Full Text] [Related]
34. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation.
Kambhampati S; Hunter B; Varnavski A; Fakhri B; Kaplan L; Ai WZ; Pampaloni M; Huang CY; Martin T; Damon L; Andreadis CB
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):246-256.e2. PubMed ID: 33288485
[TBL] [Abstract][Full Text] [Related]
35. Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.
Choi MK; Kang ES; Kim DW; Ko YH; Seok H; Park JH; Pyo DH; Hoon Lim D; Kim SJ; Kim WS
Int J Hematol; 2013 Sep; 98(3):346-54. PubMed ID: 23868695
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience.
Rassy E; Danu A; Ibrahim T; Lazarovici J; Ghez D; Michot JM; Arfi-Rouche J; Rossignol J; Vergé V; Dartigues P; Ribrag V
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e373-e380. PubMed ID: 33277224
[TBL] [Abstract][Full Text] [Related]
37. ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
Choi CW; Paek CW; Seo JH; Kim BS; Shin SW; Kim YH; Kim JS
J Korean Med Sci; 2002 Oct; 17(5):621-4. PubMed ID: 12378012
[TBL] [Abstract][Full Text] [Related]
38. Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12.
Kuruvilla J; MacDonald DA; Kouroukis CT; Cheung M; Olney HJ; Turner AR; Anglin P; Seftel M; Ismail WS; Luminari S; Couban S; Baetz T; Meyer RM; Hay AE; Shepherd L; Djurfeldt MS; Alamoudi S; Chen BE; Crump M
Blood; 2015 Aug; 126(6):733-8. PubMed ID: 26109202
[TBL] [Abstract][Full Text] [Related]
39. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
Rigacci L; Fabbri A; Puccini B; Chitarrelli I; Chiappella A; Vitolo U; Levis A; Lauria F; Bosi A
Cancer; 2010 Oct; 116(19):4573-9. PubMed ID: 20572029
[TBL] [Abstract][Full Text] [Related]
40. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
